ARTICLE | Company News
Beijing Jialin, Pfizer cardiovascular news
May 11, 2015 7:00 AM UTC
China’s Supreme People’s Court ruled invalid a patent covering crystalline formulations of Pfizer’s Lipitor atorvastatin, preventing the pharma from suing generic makers. The court said patent application CN96195564.3 did not provide sufficient detail to support its claims.
Jialin, which already markets a powder form of atorvastatin as A Le in China, had filed an invalidation petition challenging the crystalline patent. Atorvastatin is an HMG-CoA reductase inhibitor marketed to lower cholesterol and prevent cardiovascular events including heart attack and stroke. ...